Prognostic factor analysis for PFS posttreatment
| . | Univariate (log rank) . | Multivariate (Cox regression) . | |
|---|---|---|---|
| P . | Hazard ratio (95% CI) . | P . | |
| Pretreatment Bcl-2/ IgH level | .000 | 4.023 (1.990-8.135) | <.001 |
| >1 | |||
| <1 | |||
| Posttreatment Bcl-2/ IgH status | .001 | 2.694 (1.243-5.842) | .012 |
| Positive | |||
| Negative | |||
| Ann Arbor stage | .066 | 1.209 (0.467-3.130) | .696 |
| IV | |||
| ≤III | |||
| FLIPI (score) and risk groups | .182 | n.a. | |
| (≥2) intermediate and high risk | |||
| (0-1) low risk | |||
| Treatment response | .437 | n.a. | |
| CR | |||
| No CR | |||
| Treatment regimen | .629 | n.a. | |
| B-R | |||
| R-CHOP | |||
| . | Univariate (log rank) . | Multivariate (Cox regression) . | |
|---|---|---|---|
| P . | Hazard ratio (95% CI) . | P . | |
| Pretreatment Bcl-2/ IgH level | .000 | 4.023 (1.990-8.135) | <.001 |
| >1 | |||
| <1 | |||
| Posttreatment Bcl-2/ IgH status | .001 | 2.694 (1.243-5.842) | .012 |
| Positive | |||
| Negative | |||
| Ann Arbor stage | .066 | 1.209 (0.467-3.130) | .696 |
| IV | |||
| ≤III | |||
| FLIPI (score) and risk groups | .182 | n.a. | |
| (≥2) intermediate and high risk | |||
| (0-1) low risk | |||
| Treatment response | .437 | n.a. | |
| CR | |||
| No CR | |||
| Treatment regimen | .629 | n.a. | |
| B-R | |||
| R-CHOP | |||
Data on 92 patients were available for univariate and multivariate analysis; n.a. indicates not close to significance in univariate analysis (P > .1) and therefore not included in multivariate analysis.